Motivations for participating in an HIV vaccine efficacy trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 3, 2005, Pages 359-364

  Colfax, Grant ^a   Buchbinder, Susan ^a   Vamshidar, Goli ^b   Celum, Connie ^c   McKirnan, David ^d   Neidig, Judith ^e   Koblin, Beryl ^f   Gurwith, Marc ^g   Bartholow, Brad ^b  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HOWARD BROWN HEALTH CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f NEW YORK BLOOD CENTER   (United States)

^g VaxGen Inc   (United States)

Author keywords

Clinical trials; HIV; Motivations; Risk behavior; Vaccine

Indexed keywords

AIDSVAX B/B; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE; MONITORING; MOTIVATION; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; RISK REDUCTION; VACCINE PRODUCTION;

ADULT; AIDS VACCINES; ALTRUISM; COMPENSATION AND REDRESS; COUNSELING; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; MALE; MOTIVATION; PATIENT PARTICIPATION; RISK-TAKING; SEXUAL PARTNERS;

EID: 21544433525     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000152039.88422.ec     Document Type: Article

References (10)

1. Owens DK, Edwards DM, Shachter RD. Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics. AIDS. 1998;12:1057-1066.
2. Bartholow BN, MacQueen KM, Douglas JMJ, et al. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:108-115.
3. Hays RB, Kegeles SM. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. J Acquir Immune Defic Syndr. 1999;20:164-171.
4. Jenkins RA, Chinaworapong S, Morgan PA, et al. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:171-177.
5. MacQueen KM, Buchbinder S, Douglas JM, et al. The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection. AIDS Res Hum Retroviruses. 1994;10(Suppl 2): S261-S264.
6. Francis DP, Heyward WL, Popovic V, et al. Candidate HIV/AIDS vaccines: lessons learned from the world's first phase III efficacy trials. AIDS. 2003;17:147-156.
7. Halpern SD, Karlawish JH, Casarett D, et al. Hypertensive patients' willingness to participate in placebo-controlled trials: implications for recruitment efficiency. Am Heart J. 2003;146:985-992.
8. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785-793.
9. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:266-271.
10. Johnson MO. Belief of vaccine receipt in HIV vaccine trials: further cautions. J Acquir Immune Defic Syndr. 1999;21:413-416.